Skip to main content
Top

Latest pharmaceutical approaches across the spectrum of heart failure

Unlock free access to practice-relevant journal articles

Join our community of medical professionals and register now to access a handpicked selection of journal articles from Springer's Medical portfolio. 

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer. 

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe. 

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area. 

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

Published in:

Open Access 13-02-2024 | Heart Failure

Latest pharmaceutical approaches across the spectrum of heart failure

Authors: Dimitrios Bismpos, Jan Wintrich, Julian Hövelmann, Michael Böhm

Published in: Heart Failure Reviews | Issue 3/2024

Login to get access

Abstract

Despite major advances in prevention and medical therapy, heart failure (HF) remains associated with high morbidity and mortality, especially in older and frailer patients. Therefore, a complete, guideline-based treatment is essential, even in HF patients with conditions traditionally associated with a problematic initiation and escalation of the medical HF therapy, such as chronic kidney disease and arterial hypotension, as the potential adverse effects are overcome by the overall decrease of the absolute risk. Furthermore, since the latest data suggest that the benefit of a combined medical therapy (MRA, ARNI, SGLT2i, beta-blocker) may extend up to a LVEF of 65%, further trials on these subgroups of patients (HFmrEF, HFpEF) are needed to re-evaluate the guideline-directed medical therapy across the HF spectrum. In particular, the use of SGLT2i was recently extended to HFpEF patients, as evidenced by the DELIVER and EMPEROR-preserved trials. Moreover, the indication for other conservative treatments in HF patients, such as the intravenous iron supplementation, was accordingly strengthened in the latest guidelines. Finally, the possible implementation of newer substances, such as finerenone, in guideline-directed medical practice for HF is anticipated with great interest.
Literature
1.
go back to reference McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 195. https://doi.org/10.1093/eurheartj/ehad195. (Epub ahead of print. PMID: 37622666)CrossRef McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 195. https://​doi.​org/​10.​1093/​eurheartj/​ehad195. (Epub ahead of print. PMID: 37622666)CrossRef
2.
go back to reference McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021(42):3599–3726 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021(42):3599–3726
3.
go back to reference Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145:e895–e1032PubMed Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145:e895–e1032PubMed
5.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128. (Epub 2016 May 20. Erratum in: Eur Heart J 2016 Dec 30; PMID: 27206819)CrossRefPubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. https://​doi.​org/​10.​1093/​eurheartj/​ehw128. (Epub 2016 May 20. Erratum in: Eur Heart J 2016 Dec 30; PMID: 27206819)CrossRefPubMed
6.
go back to reference Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators and Coordinators (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54–61PubMedCrossRef Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, PARADIGM-HF Investigators and Coordinators (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54–61PubMedCrossRef
7.
go back to reference McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMedCrossRef McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMedCrossRef
8.
go back to reference Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424PubMedCrossRef Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424PubMedCrossRef
9.
go back to reference Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld J, McGuire DK, Nassif ME, O’Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ (2021) In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol 78:2004–2012PubMedPubMedCentralCrossRef Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld J, McGuire DK, Nassif ME, O’Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ (2021) In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol 78:2004–2012PubMedPubMedCentralCrossRef
11.
go back to reference Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, Cole GD (2017) The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 19:1401–1409PubMedCrossRef Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, Cole GD (2017) The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 19:1401–1409PubMedCrossRef
13.
go back to reference Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396:121–128PubMedCrossRef Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396:121–128PubMedCrossRef
14.
go back to reference Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, Tay WT, Dickstein K, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Lam CSP, Filippatos G, Collins SP (2020) Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health 8:e411–e422PubMedCrossRef Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, Tay WT, Dickstein K, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Lam CSP, Filippatos G, Collins SP (2020) Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health 8:e411–e422PubMedCrossRef
15.
go back to reference Borlaug BA, Redfield MM (2011) Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123:2006–2013PubMedPubMedCentralCrossRef Borlaug BA, Redfield MM (2011) Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123:2006–2013PubMedPubMedCentralCrossRef
17.
go back to reference Böhm M, Bewarder Y, Kindermann I (2020) Ejection fraction in heart failure revisited- where does the evidence start? Eur Heart J 41:2363–2365PubMedCrossRef Böhm M, Bewarder Y, Kindermann I (2020) Ejection fraction in heart failure revisited- where does the evidence start? Eur Heart J 41:2363–2365PubMedCrossRef
18.
go back to reference Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S (2021) Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23:352–380PubMedCrossRef Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S (2021) Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23:352–380PubMedCrossRef
19.
go back to reference Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Investigators (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461PubMedCrossRef Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, EMPEROR-Preserved Trial Investigators (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461PubMedCrossRef
20.
go back to reference Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, DELIVER Trial Committees and Investigators (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098PubMedCrossRef Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, DELIVER Trial Committees and Investigators (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098PubMedCrossRef
21.
go back to reference Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial. Circulation 145:184–193PubMedCrossRef Butler J, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD (2022) Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial. Circulation 145:184–193PubMedCrossRef
22.
go back to reference Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28:1956–1964PubMedPubMedCentralCrossRef Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28:1956–1964PubMedPubMedCentralCrossRef
23.
go back to reference Butler J, Siddiqi TJ, Filippatos G, Ferreira JP, Pocock SJ, Zannad F, Anker SD (2022) Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. Eur J Heart Fail 24:245–248PubMedCrossRef Butler J, Siddiqi TJ, Filippatos G, Ferreira JP, Pocock SJ, Zannad F, Anker SD (2022) Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. Eur J Heart Fail 24:245–248PubMedCrossRef
24.
go back to reference Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD (2022) Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 7:1259–1263PubMedPubMedCentralCrossRef Vaduganathan M, Claggett BL, Jhund P, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Hegde SM, Lindholm D, Petersson M, Langkilde AM, McMurray JJV, Solomon SD (2022) Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 7:1259–1263PubMedPubMedCentralCrossRef
25.
go back to reference Vaduganathan M, Claggett BL, Inciardi RM, Fonarow GC, McMurray JJV, Solomon SD (2022) Estimating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction. Circulation 145:1741–1743PubMedCrossRef Vaduganathan M, Claggett BL, Inciardi RM, Fonarow GC, McMurray JJV, Solomon SD (2022) Estimating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction. Circulation 145:1741–1743PubMedCrossRef
26.
go back to reference Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620. https://doi.org/10.1056/NEJMoa1908655. (Epub 2019 Sep 1. PMID: 31475794)CrossRefPubMed Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, PARAGON-HF Investigators and Committees (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609–1620. https://​doi.​org/​10.​1056/​NEJMoa1908655. (Epub 2019 Sep 1. PMID: 31475794)CrossRefPubMed
27.
go back to reference Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, Sharma K, Solomon SD, Starling RC, Velazquez EJ, Williamson K, Zieroth S, Braunwald E (2023) Rationale, design and baseline characteristics of the PARAGLIDE-HF Trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event. J Card Fail 1071–9164(23):00040–4. https://doi.org/10.1016/j.cardfail.2023.02.001. (Epub ahead of print. PMID: 36796671)CrossRef Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, Sharma K, Solomon SD, Starling RC, Velazquez EJ, Williamson K, Zieroth S, Braunwald E (2023) Rationale, design and baseline characteristics of the PARAGLIDE-HF Trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event. J Card Fail 1071–9164(23):00040–4. https://​doi.​org/​10.​1016/​j.​cardfail.​2023.​02.​001. (Epub ahead of print. PMID: 36796671)CrossRef
29.
go back to reference Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34:816–829PubMedCrossRef Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34:816–829PubMedCrossRef
30.
go back to reference Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF Investigators (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895–1904 (Epub ahead of print. PMID: 36796671)PubMedCrossRef Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF Investigators (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895–1904 (Epub ahead of print. PMID: 36796671)PubMedCrossRef
32.
go back to reference Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, IRONMAN Study Group (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199–2209CrossRef Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, IRONMAN Study Group (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199–2209CrossRef
33.
go back to reference Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M (2023) Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail 10(2):1473–1480PubMedPubMedCentralCrossRef Salah HM, Savarese G, Rosano GMC, Ambrosy AP, Mentz RJ, Fudim M (2023) Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail 10(2):1473–1480PubMedPubMedCentralCrossRef
34.
go back to reference Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, Rosano GMC, Jankowska EA, Anker SD, Lund LH, Savarese G (2021) Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail 23:1844–1854PubMedCrossRef Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, Rosano GMC, Jankowska EA, Anker SD, Lund LH, Savarese G (2021) Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail 23:1844–1854PubMedCrossRef
35.
go back to reference Mitrovic V, Jovanovic A, Lehinant S (2011) Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep 8:38–44PubMedCrossRef Mitrovic V, Jovanovic A, Lehinant S (2011) Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep 8:38–44PubMedCrossRef
36.
go back to reference Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, VICTORIA Study Group (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893PubMedCrossRef Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, VICTORIA Study Group (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893PubMedCrossRef
37.
go back to reference Senni M, Lopez-Sendon J, Cohen-Solal A, Ponikowski P, Nkulikiyinka R, Freitas C, Vlajnic VM, Roessig L, Pieske B (2022) Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail 9(6):3791–3803. https://doi.org/10.1002/ehf2.14050. (Epub 2022 Jul 26. PMID: 35880474; PMCID: PMC9773767)CrossRefPubMedPubMedCentral Senni M, Lopez-Sendon J, Cohen-Solal A, Ponikowski P, Nkulikiyinka R, Freitas C, Vlajnic VM, Roessig L, Pieske B (2022) Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. ESC Heart Fail 9(6):3791–3803. https://​doi.​org/​10.​1002/​ehf2.​14050. (Epub 2022 Jul 26. PMID: 35880474; PMCID: PMC9773767)CrossRefPubMedPubMedCentral
38.
go back to reference Teerlink JR, Felker GM, McMurray JJ et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895–2903PubMedCrossRef Teerlink JR, Felker GM, McMurray JJ et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895–2903PubMedCrossRef
39.
go back to reference Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE, GALACTIC-HF Investigators (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384:105–116PubMedCrossRef Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O’Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE, GALACTIC-HF Investigators (2021) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 384:105–116PubMedCrossRef
40.
go back to reference Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlström U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsányi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol 7:26–33PubMedCrossRef Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlström U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsányi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR (2022) Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol 7:26–33PubMedCrossRef
41.
go back to reference Lewis GD, Voors AA, Cohen-Solal A et al (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA 328(3):259–269PubMedPubMedCentralCrossRef Lewis GD, Voors AA, Cohen-Solal A et al (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA 328(3):259–269PubMedPubMedCentralCrossRef
42.
go back to reference Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial Investigators (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 384(2):117–128. https://doi.org/10.1056/NEJMoa2030183. (Epub 2020 Nov 16. PMID: 33200892)CrossRefPubMed Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial Investigators (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 384(2):117–128. https://​doi.​org/​10.​1056/​NEJMoa2030183. (Epub 2020 Nov 16. PMID: 33200892)CrossRefPubMed
45.
go back to reference Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA (2018) Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 271:132–139PubMedCrossRef Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Voors AA (2018) Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol 271:132–139PubMedCrossRef
46.
go back to reference Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol 7:1227–1234PubMedPubMedCentralCrossRef Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol 7:1227–1234PubMedPubMedCentralCrossRef
47.
go back to reference Böhm M, Ewen S (2017) Blood pressure risk associations in heart failure: true effects or inverse causality? JACC Heart Fail 5:820–822PubMedCrossRef Böhm M, Ewen S (2017) Blood pressure risk associations in heart failure: true effects or inverse causality? JACC Heart Fail 5:820–822PubMedCrossRef
48.
go back to reference Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38:1132–1143PubMedPubMedCentralCrossRef Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38:1132–1143PubMedPubMedCentralCrossRef
49.
go back to reference Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 41:3402–3418PubMedPubMedCentralCrossRef Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 41:3402–3418PubMedPubMedCentralCrossRef
50.
go back to reference Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schüler E, Ponikowski P, Wanner C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. J Am Coll Cardiol 78:1337–1348PubMedCrossRef Böhm M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Mahfoud F, Brueckmann M, Jamal W, Ofstad AP, Schüler E, Ponikowski P, Wanner C, Zannad F, Packer M, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure. J Am Coll Cardiol 78:1337–1348PubMedCrossRef
53.
go back to reference Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, Hage C, Dahlström U, Sinagra G, Savarese G (2022) Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 24:1047–1062PubMedCrossRef Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, Hage C, Dahlström U, Sinagra G, Savarese G (2022) Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 24:1047–1062PubMedCrossRef
55.
go back to reference Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV (2019) Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 74(5):601–612. https://doi.org/10.1016/j.jacc.2019.05.052. (PMID: 31370950)CrossRefPubMed Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV (2019) Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 74(5):601–612. https://​doi.​org/​10.​1016/​j.​jacc.​2019.​05.​052. (PMID: 31370950)CrossRefPubMed
56.
go back to reference Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD, EMPEROR-Preserved Trial Committees and Investigators (2022) Empagliflozin improves outcomes in patients with heart preserved left ventricular ejection fraction and preserved ejection fraction irrespective of age. J Am Coll Cardiol 80:1–18PubMedCrossRef Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD, EMPEROR-Preserved Trial Committees and Investigators (2022) Empagliflozin improves outcomes in patients with heart preserved left ventricular ejection fraction and preserved ejection fraction irrespective of age. J Am Coll Cardiol 80:1–18PubMedCrossRef
57.
go back to reference Pellicori P, Cleland JGF (2022) Heart failure: age is no excuse for complacency. Eur J Heart Fail 24:1063–1065PubMedCrossRef Pellicori P, Cleland JGF (2022) Heart failure: age is no excuse for complacency. Eur J Heart Fail 24:1063–1065PubMedCrossRef
58.
go back to reference Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ (2023) Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 118:3434–3450PubMedCrossRef Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ (2023) Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 118:3434–3450PubMedCrossRef
59.
go back to reference Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA (2017) Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136:6–19PubMedPubMedCentralCrossRef Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA (2017) Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136:6–19PubMedPubMedCentralCrossRef
60.
go back to reference Reddy YNV, Lewis GD, Shah SJ et al (2019) Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc 94:1199–1209PubMedCrossRef Reddy YNV, Lewis GD, Shah SJ et al (2019) Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc 94:1199–1209PubMedCrossRef
61.
go back to reference Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC (2023) Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail 11(8 Pt 1):1000–1010. https://doi.org/10.1016/j.jchf.2023.05.010. (Epub 2023 May 21 PMID: 37294245)CrossRefPubMed Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC (2023) Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail 11(8 Pt 1):1000–1010. https://​doi.​org/​10.​1016/​j.​jchf.​2023.​05.​010. (Epub 2023 May 21 PMID: 37294245)CrossRefPubMed
62.
go back to reference Reddy YNV, Anantha-Narayanan M, Obokata M et al (2019) Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. J Am Coll Cardiol HF 7:678–687 Reddy YNV, Anantha-Narayanan M, Obokata M et al (2019) Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis. J Am Coll Cardiol HF 7:678–687
63.
go back to reference Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389(12):1069–1084PubMedCrossRef Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389(12):1069–1084PubMedCrossRef
64.
go back to reference Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M (2021) Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 78:330–343PubMedPubMedCentralCrossRef Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M (2021) Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 78:330–343PubMedPubMedCentralCrossRef
65.
go back to reference Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N (2019) Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140:303–315PubMedCrossRef Kidokoro K, Cherney DZI, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N (2019) Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140:303–315PubMedCrossRef
66.
go back to reference Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O’Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143:298–309PubMedCrossRef Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O’Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 143:298–309PubMedCrossRef
67.
go back to reference Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, Green JB, Rosenstock J, Schnaidt S, Brueckmann M, Pocock SJ, Packer M, Anker SD, EMPEROR-Preserved Trial Committees and Investigators (2022) Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 146:676–686PubMedPubMedCentralCrossRef Filippatos G, Butler J, Farmakis D, Zannad F, Ofstad AP, Ferreira JP, Green JB, Rosenstock J, Schnaidt S, Brueckmann M, Pocock SJ, Packer M, Anker SD, EMPEROR-Preserved Trial Committees and Investigators (2022) Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 146:676–686PubMedPubMedCentralCrossRef
68.
go back to reference Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A (2021) Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99:750–762PubMedCrossRef Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, Heerspink HJL, Ritter I, von Eynatten M, Zinman B, Inzucchi SE, Wanner C, Koitka-Weber A (2021) Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99:750–762PubMedCrossRef
69.
go back to reference Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Vaduganathan M, Jhund PS, McMurray JJV (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146:438–449PubMedPubMedCentralCrossRef Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Vaduganathan M, Jhund PS, McMurray JJV (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146:438–449PubMedPubMedCentralCrossRef
70.
go back to reference Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446PubMedCrossRef Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446PubMedCrossRef
71.
go back to reference EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233CrossRef EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://​doi.​org/​10.​1056/​NEJMoa2204233CrossRef
72.
go back to reference Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179:3220–3234PubMedCrossRef Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 179:3220–3234PubMedCrossRef
73.
go back to reference Bakris GL, Agarwal R, Anker SD et al (2020) FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229PubMedCrossRef Bakris GL, Agarwal R, Anker SD et al (2020) FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229PubMedCrossRef
75.
go back to reference Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474–484PubMedCrossRef Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474–484PubMedCrossRef
76.
go back to reference Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, Friede T, Fabien V, Kosiborod M, Metra M, Piña IL, Pinto F, Rossignol P, van der Meer P, Bahit C, Belohlavek J, Böhm M, Brugts JJ, Cleland JGF, Ezekowitz J, Bayes-Genis A, Gotsman I, Goudev A, Khintibidze I, Lindenfeld J, Mentz RJ, Merkely B, Montes EC, Mullens W, Nicolau JC, Parkhomenko A, Ponikowski P, Seferovic PM, Senni M, Shlyakhto E, Cohen-Solal A, Szecsödy P, Jensen K, Dorigotti F, Weir MR, Pitt B (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362–4373. https://doi.org/10.1093/eurheartj/ehac401.PMID:35900838;PMCID:PMC9622299CrossRefPubMedPubMedCentral Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, Friede T, Fabien V, Kosiborod M, Metra M, Piña IL, Pinto F, Rossignol P, van der Meer P, Bahit C, Belohlavek J, Böhm M, Brugts JJ, Cleland JGF, Ezekowitz J, Bayes-Genis A, Gotsman I, Goudev A, Khintibidze I, Lindenfeld J, Mentz RJ, Merkely B, Montes EC, Mullens W, Nicolau JC, Parkhomenko A, Ponikowski P, Seferovic PM, Senni M, Shlyakhto E, Cohen-Solal A, Szecsödy P, Jensen K, Dorigotti F, Weir MR, Pitt B (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362–4373. https://​doi.​org/​10.​1093/​eurheartj/​ehac401.​PMID:​35900838;PMCID:​PMC9622299CrossRefPubMedPubMedCentral
77.
go back to reference Shlipak MG, Matsushita K, Ärnlöv J et al (2013) Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369(10):932–943PubMedPubMedCentralCrossRef Shlipak MG, Matsushita K, Ärnlöv J et al (2013) Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369(10):932–943PubMedPubMedCentralCrossRef
78.
go back to reference Pinsino A, Carey MR, Husain S et al (2023) The difference between cystatin C- and creatinine-based estimated GFR in heart failure with reduced ejection fraction: insights from PARADIGM-HF. Am J Kidney Dis 82(5):521–533PubMedCrossRef Pinsino A, Carey MR, Husain S et al (2023) The difference between cystatin C- and creatinine-based estimated GFR in heart failure with reduced ejection fraction: insights from PARADIGM-HF. Am J Kidney Dis 82(5):521–533PubMedCrossRef
79.
80.
go back to reference Braun GS, Kittelmann K, Floege J (2021) Akute Nierenschädigung bei kardiorenalem Syndrom Nephrologe 16:71–80 Braun GS, Kittelmann K, Floege J (2021) Akute Nierenschädigung bei kardiorenalem Syndrom Nephrologe 16:71–80
82.
go back to reference McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ (2020) Acute kidney function declines in the context of decongestion in acute decompensated heart failure. JACC Heart Fail 8:537–547PubMedPubMedCentralCrossRef McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, Sarnak MJ (2020) Acute kidney function declines in the context of decongestion in acute decompensated heart failure. JACC Heart Fail 8:537–547PubMedPubMedCentralCrossRef
83.
go back to reference Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M, ADVOR Study Group (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387:1185–1195PubMedCrossRef Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M, ADVOR Study Group (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387:1185–1195PubMedCrossRef
84.
go back to reference Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, von Haehling S, Schumacher U, Möbius-Winkler S, Busch M (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146:289–298PubMedCrossRef Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, von Haehling S, Schumacher U, Möbius-Winkler S, Busch M (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146:289–298PubMedCrossRef
86.
go back to reference Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, Dávila-Ramos MF, Llácer P, Salamanca-Bautista P, Pérez-Silvestre J, Plasín MÁ, Cerqueiro JM, Gil P, Formiga F, Manzano L, CLOROTIC trial investigators (2022) Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehac689CrossRef Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, Dávila-Ramos MF, Llácer P, Salamanca-Bautista P, Pérez-Silvestre J, Plasín MÁ, Cerqueiro JM, Gil P, Formiga F, Manzano L, CLOROTIC trial investigators (2022) Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. https://​doi.​org/​10.​1093/​eurheartj/​ehac689CrossRef
88.
go back to reference Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH, ESC-EORP-HFA Heart Failure Long-Term Registry Investigators (2019) Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 21:1338–1352PubMedCrossRef Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH, ESC-EORP-HFA Heart Failure Long-Term Registry Investigators (2019) Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 21:1338–1352PubMedCrossRef
89.
go back to reference Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28:568–574PubMedPubMedCentralCrossRef Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28:568–574PubMedPubMedCentralCrossRef
90.
go back to reference Matsukawa R, Masuda S, Matsuura H, Nakashima H, Ikuta H, Okabe K, Okahara A, Kawai S, Tokutome M, Tobushi T, Mukai Y (2021) Early follow-up at outpatient care after discharge improves long-term heart failure readmission rate and prognosis. ESC Heart Fail 8:3002–3013PubMedPubMedCentralCrossRef Matsukawa R, Masuda S, Matsuura H, Nakashima H, Ikuta H, Okabe K, Okahara A, Kawai S, Tokutome M, Tobushi T, Mukai Y (2021) Early follow-up at outpatient care after discharge improves long-term heart failure readmission rate and prognosis. ESC Heart Fail 8:3002–3013PubMedPubMedCentralCrossRef
91.
go back to reference Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938–1952PubMedCrossRef Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400:1938–1952PubMedCrossRef
92.
go back to reference Greene SJ, Fonarow GC, DeVore AD et al (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365–2383PubMedPubMedCentralCrossRef Greene SJ, Fonarow GC, DeVore AD et al (2019) Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73(19):2365–2383PubMedPubMedCentralCrossRef
Metadata
Title
Latest pharmaceutical approaches across the spectrum of heart failure
Authors
Dimitrios Bismpos
Jan Wintrich
Julian Hövelmann
Michael Böhm
Publication date
13-02-2024
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 3/2024
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-024-10389-8